BrMT was first isolated from the mucus of Calliostoma canaliculatum, a cone snail found in the temperate coastal waters of the western Pacific. BrMT is the first compound found in the hypobranchial gland mucus to produce a biological response.[1]
BrMT is a brominated tryptamine. It has a thiol group, allowing dimerization via a disulfide linkage.[1] BrMT is found to be light-sensitive and unstable in a reducing environment. Its first total synthesis was reported in 2013.[2]
Target
Calliostoma canaliculatum deters predators by covering its shells with BrMT-containing mucus, in particular when exposed to a predator, such as Pycnopodia helianthoides or Pisaster giganteus.[3]
The BrMT dimer is known to affect voltage-gated potassium channels in the central nervous system. It strongly inhibits ShBΔ potassium channels, and to a lesser degree also isoforms found in humans (hKv1.1) and squid (sqKv1.A). It also affects members of Kv4 family (Kv4.1 and Kv4.2) and Drosophilaether-à-go-go channels.[1]
Mode of action
The mode of action of BrMT involves inhibition of specific voltage gated potassium channels present in the nervous system. By stabilizing the voltage sensor of the ion channel, the opening of ShBΔ ion channels and other Kv1 members is inhibited.[2] BrMT has an Шаблон:IC50 of 1.1 ± 0.1 μM on ShBΔ channels, a member of the Kv1 family.[4] The BrMT binding to ShBΔ has been found to be allosteric in nature, due to a change of conformation in the K+ channel subunits and not by blocking the entrance of the channel.[4][5]
2.png){kind=link}